bioAffinity Technologies, Inc. announced that a real world clinical case study demonstrated the clinical utility of its CyPath Lung noninvasive diagnostic test in supporting management decisions for a high risk patient with multiple small pulmonary nodules under Lung-RADS surveillance. The case involved a smoker with subcentimeter nodules classified as Lung-RADS 3, where a negative CyPath Lung result supported continued CT surveillance rather than escalation to invasive diagnostics. The disclosure positions CyPath Lung as an adjunctive tool in the evaluation of indeterminate nodules below two centimeters, a persistent grey zone in lung cancer screening.

Why this case matters more than another performance metric update

Industry observers note that single patient case studies rarely move the needle in diagnostics, particularly in lung cancer where sensitivity and specificity claims are already well populated. What makes this disclosure different is not the reported performance metrics, which have already been published, but the framing of CyPath Lung as a decision stabilizer rather than a replacement diagnostic. The case explicitly addresses one of the most unresolved problems in lung cancer screening programs: what to do with small nodules that are unlikely to be malignant but psychologically and clinically difficult to ignore.

Low dose CT screening has expanded rapidly, but its success has exposed a secondary challenge. The majority of detected nodules fall into indeterminate categories that trigger serial imaging, anxiety, and in some cases unnecessary invasive procedures. CyPath Lung is being positioned not as a rule out or rule in test, but as a confidence modifier layered onto existing guidelines. That distinction matters for adoption because it lowers the bar for clinical acceptance while still addressing a real pain point.

What CyPath Lung actually adds beyond imaging and why that distinction matters

Clinicians tracking the field emphasize that CT imaging already performs well at detecting nodules, but performs poorly at characterizing biological behavior at very small sizes. CyPath Lung approaches the problem orthogonally by interrogating sputum derived cellular populations using flow cytometry and artificial intelligence rather than anatomical imaging. This biological signal is not competing with CT. It is supplementing it.

In the reported case, the nodules were between 3 and 7 millimeters, a size range where biopsy is impractical and PET imaging lacks sensitivity. In that context, a negative CyPath Lung result does not eliminate cancer risk, but it shifts perceived probability enough to justify staying the course with guideline consistent surveillance. That is a subtle but important contribution. It reframes diagnostics as probabilistic reinforcement rather than binary determination.

Sensitivity and specificity sound strong but context determines their real world meaning

The company continues to cite 92 percent sensitivity, 87 percent specificity, and 88 percent accuracy in nodules under 20 millimeters. On paper, these numbers compare favorably with blood based assays and imaging adjuncts. However, regulatory watchers suggest that the true test of clinical relevance is not headline accuracy but how the test behaves in low prevalence populations where false positives and false reassurance can distort outcomes.

In Lung-RADS 3 populations, the pretest probability of malignancy is already low. A test that meaningfully reduces uncertainty without encouraging premature discharge from surveillance could be valuable. Conversely, any tendency toward false reassurance could be clinically problematic. The reported case reinforces appropriate use rather than overreach by explicitly supporting continued CT follow up rather than discontinuation.

Why the Laboratory Developed Test pathway both helps and limits CyPath Lung

CyPath Lung is marketed as a Laboratory Developed Test through Precision Pathology Laboratory Services, which allows faster market entry but also constrains scalability and reimbursement predictability. Industry analysts point out that the LDT pathway suits adjunctive diagnostics aimed at specialized clinical decision points, but it can also limit payer coverage and national adoption unless supported by stronger real world evidence.

This case study is a step toward demonstrating utility rather than performance, but it is not yet the kind of multicenter evidence payers typically require. The company appears aware of this and is carefully positioning CyPath Lung as complementary to guidelines rather than disruptive to them. That positioning reduces regulatory friction but also slows the path to broad reimbursement mandates.

How this compares with liquid biopsy and blood based lung cancer tests

The lung cancer diagnostics space is increasingly crowded with blood based assays promising early detection. Compared with circulating tumor DNA approaches, CyPath Lung occupies a narrower but arguably more defensible niche. It targets patients who already have imaging findings rather than attempting population wide screening.

Clinicians observing adoption trends note that blood based tests struggle when tumor burden is extremely low, which is often the case with subcentimeter nodules. Sputum based cellular analysis may offer a different signal profile in this context. However, sputum collection quality, patient compliance, and laboratory standardization remain practical challenges that could limit consistency outside controlled settings.

Clinical workflow impact is the real battleground, not diagnostic supremacy

The strongest implication of the case study is not diagnostic superiority but workflow alignment. CyPath Lung fits into existing pulmonology pathways without forcing clinicians to abandon Lung-RADS or imaging based surveillance. It adds a layer of biological reassurance that may reduce pressure to escalate care prematurely.

Healthcare systems increasingly prioritize avoiding unnecessary procedures, not just detecting disease. From that perspective, a test that helps clinicians confidently wait can be as valuable as one that prompts action. Industry observers suggest this positioning may resonate particularly in integrated health systems focused on value based care.

Risks and unresolved questions that still limit broader confidence

Despite the positive framing, several questions remain unresolved. The evidence base is still thin, relying on case studies and limited clinical cohorts rather than large prospective trials. The reliance on advanced flow cytometry and proprietary algorithms raises questions about reproducibility across laboratories. Reimbursement remains uncertain, particularly as payers scrutinize adjunctive diagnostics more aggressively.

There is also the risk of perception drift. If CyPath Lung begins to be interpreted as a rule out test rather than a risk stratifier, misuse could follow. The company’s messaging so far has avoided that trap, but real world utilization often diverges from intended use.

What clinicians, regulators, and industry observers are likely to watch next

Clinicians will be watching for larger real world datasets showing consistent performance across diverse populations and practice settings. Regulators will focus on how the test is positioned relative to screening guidelines and whether expanded claims are pursued. Industry analysts will monitor whether bioAffinity Technologies can translate niche clinical utility into sustainable reimbursement and volume growth.

If CyPath Lung can demonstrate that it reliably reduces unnecessary invasive procedures without increasing missed cancers, its value proposition strengthens materially. If not, it risks being perceived as an interesting but optional add on in an already complex diagnostic landscape.

  bioAffinity Technologies, CyPath Lung, flow cytometry, lung cancer diagnostics, Lung-RADS, noninvasive diagnostics, pulmonary nodules